Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA
First patients recruited for bladder cancer recurrence monitoring study
News provided by
Share this article
SUNDERLAND, England, July 27, 2021 /PRNewswire/
ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe.
ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for
/PRNewswire/ LIPAC Oncology LLC., a pharmaceutical company utilizing its next generation precision liposomal technology to locally deliver taxanes to target.
/PRNewswire/ AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that positive Phase 1 testing data was presented at the 2021 ASCO.
Sponsored Story
By StoryStudio April 1, 2021 4:35 pm
(BPT) – In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in